- Home
- NIE vs PRTA Comparison
NIE vs PRTA Comparison
Compare NIE & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIE
- PRTA
- Stock Information
- Founded
- NIE 2007
- PRTA 2012
- Country
- NIE United States
- PRTA Ireland
- Employees
- NIE N/A
- PRTA N/A
- Industry
- NIE Investment Managers
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- NIE Finance
- PRTA Health Care
- Exchange
- NIE Nasdaq
- PRTA Nasdaq
- Market Cap
- NIE 676.4M
- PRTA 472.1M
- IPO Year
- NIE N/A
- PRTA N/A
- Fundamental
- Price
- NIE $24.95
- PRTA $8.21
- Analyst Decision
- NIE
- PRTA Buy
- Analyst Count
- NIE 0
- PRTA 10
- Target Price
- NIE N/A
- PRTA $12.29
- AVG Volume (30 Days)
- NIE 70.5K
- PRTA 970.7K
- Earning Date
- NIE 01-01-0001
- PRTA 11-11-2025
- Dividend Yield
- NIE 9.04%
- PRTA N/A
- EPS Growth
- NIE N/A
- PRTA N/A
- EPS
- NIE N/A
- PRTA N/A
- Revenue
- NIE N/A
- PRTA $10,341,000.00
- Revenue This Year
- NIE N/A
- PRTA N/A
- Revenue Next Year
- NIE N/A
- PRTA $389.77
- P/E Ratio
- NIE N/A
- PRTA N/A
- Revenue Growth
- NIE N/A
- PRTA N/A
- 52 Week Low
- NIE $18.61
- PRTA $4.32
- 52 Week High
- NIE $22.47
- PRTA $22.71
- Technical
- Relative Strength Index (RSI)
- NIE 58.57
- PRTA 53.10
- Support Level
- NIE $24.53
- PRTA $8.19
- Resistance Level
- NIE $25.40
- PRTA $8.50
- Average True Range (ATR)
- NIE 0.19
- PRTA 0.35
- MACD
- NIE 0.02
- PRTA -0.08
- Stochastic Oscillator
- NIE 51.14
- PRTA 21.65
About NIE Virtus Equity & Convertible Income Fund of Beneficial Interest
Virtus AllianzGI Equity & Convertible Income Fund is a diversified, closed-end management investment company. The investment objective is to seek total return comprised of capital appreciation, current income, and gains. The fund pursues its objective by investing in a diversified portfolio of equity securities and income-producing convertible securities. Its portfolio of investments comprises different sector investments, such as aerospace and defense, banks, IT services, software, and others.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.